Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2018

Quarterly Financial Information Disclosure [Abstract]

NOTE 13 – QUARTERLY FINANCIAL DATA (UNAUDITED)

The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December 31, 2018. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All data is in thousands except per share data.

	2018												2017
	Q1			Q2			Q3			Q4			Q1			Q2			Q3			Q4
Revenues	$	12,637		$	21,416		$	23,562		$	26,837		$	3,425		$	8,253		$	11,812		$	13,077
Expenses		33,634			40,556			39,803			47,609			20,217			21,021			24,847			26,843
Net loss		(20,187	)		(16,640	)		(12,843	)		(19,219	)		(16,632	)		(12,491	)		(12,354	)		(13,091	)
Net loss attributable to non-controlling interest		—			—			—			(555	)		—			—			—			—
Net loss attributable to Sangamo Therapeutics, Inc.		(20,187	)		(16,640	)		(12,843	)		(18,664	)		(16,632	)		(12,491	)		(12,354	)		(13,091	)
Basic and Diluted Net loss per share attributable to Sangamo Therapeutics, Inc.		(0.23	)		(0.17	)		(0.13	)		(0.18	)		(0.23	)		(0.17	)		(0.15	)		(0.15	)